Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.